Inhibition of miR‐578 through SOCS2‐dependent manner reverses gefitinib resistance in NSCLC cells

Author:

Yang Bo1ORCID,Yao Lei1,Yang Liankai1,Zhao Fang1,Zhou Wenyan1

Affiliation:

1. Department of Thoracic Surgery Cangzhou Central Hospital Cangzhou Hebei Province China

Abstract

AbstractBackgroundNonsmall‐cell lung cancer (NSCLC) has emerged as one of the dreadful lung cancers globally due to its increased mortality rates. Concerning chemotherapy, gefitinib has been employed as an effective first‐line treatment drug for NSCLC. Nonetheless, the acquired resistance to gefitinib has remained one of the treatment obstacles of NSCLC, requiring improvement in the therapeutic effect of gefitinib.MethodsInitially, reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR), and Western blotting (WB) analyses were conducted to measure micro‐ribose nucleic acid (miRNA, specifically miR‐578) and suppressor of cytokine signaling 2 (SOCS2) levels in the clinical samples. Further, NSCLC cell lines resistance to gefitinib, established in vitro, were transfected by miR‐578 inhibitor, miR‐578 mimic, and si‐SOCS2. Similarly, the xenograft mouse model in vivo was constructed to validate the reversing effect of miR‐578.ResultsOur findings indicated the increased miR‐578 expression levels in the gefitinib resistance group. Further, inhibiting the miR‐578 expression substantially reversed the gefitinib resistance. In addition, the miR‐578 effect was modulated via the SOCS2 expression level. The decreased gefitinib resistance effect of miR‐578 was weakened by inhibiting the SOCS2 expression.ConclusionThese findings demonstrated that miR‐578 effectively abolished gefitinib resistance by regulating the SOCS2 expression within NSCLC cells in vitro and in vivo. Together, these results will undoubtedly support a reference to provide potential molecular therapeutic targets and clinical treatments for treating NSCLC patients.

Publisher

Wiley

Subject

Health, Toxicology and Mutagenesis,Management, Monitoring, Policy and Law,Toxicology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3